Arbutus Biopharma Corp (ABUS) Shareholder Equity
- 2026-06-30: Common Stock, Value, IssuedCAD (m); Common Stock, Value, IssuedUSD $1.45B; Additional Paid in CapitalCAD (m); Additional Paid in CapitalUSD $74.32M.
- 2026-03-31: Common Stock, Value, IssuedCAD (m); Common Stock, Value, IssuedUSD $1.44B; Additional Paid in CapitalCAD (m); Additional Paid in CapitalUSD $74.26M.
- 2025-12-31: Common Stock, Value, IssuedCAD (m); Common Stock, Value, IssuedUSD $1.42B; Additional Paid in CapitalCAD (m); Additional Paid in CapitalUSD $83.32M.
- 2025-09-30: Common Stock, Value, IssuedCAD (m); Common Stock, Value, IssuedUSD $1.42B; Additional Paid in CapitalCAD (m); Additional Paid in CapitalUSD $83.28M.
Arbutus Biopharma Corp Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Common Stock, Value, Issued CAD | Common Stock, Value, Issued USD | Additional Paid in Capital CAD | Additional Paid in Capital USD | Accumulated Other Comprehensive Income (Loss), Net of Tax CAD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) CAD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent CAD | Stockholders' Equity Attributable to Parent USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD | Preferred Stock, Value, Issued USD | Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax USD | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs CAD | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs USD | Adjustments to Additional Paid in Capital, Warrant Issued CAD | APIC, Share-based Payment Arrangement, Recognition and Exercise CAD | APIC, Share-based Payment Arrangement, Recognition and Exercise USD |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $1.45B | (m) | $74.32M | (m) | $-48.24M | (m) | $-1.22B | (m) | $258.73M | 3 month · $1.62M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | (m) | $1.44B | (m) | $74.26M | (m) | $-48.20M | (m) | $-1.21B | (m) | $260.18M | 3 month · $1.36M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | (m) | $1.42B | (m) | $83.32M | (m) | $-48.10M | (m) | $-1.38B | (m) | $76.58M | 12 month · $6.95M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | (m) | $1.42B | (m) | $83.28M | (m) | $-48.13M | (m) | $-1.38B | (m) | $77.40M | 3 month · $1.26M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | (m) | $1.42B | (m) | $82.63M | (m) | $-48.19M | (m) | $-1.37B | (m) | $82.98M | 3 month · $864.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | (m) | $1.42B | (m) | $82.09M | (m) | $-48.17M | (m) | $-1.37B | (m) | $79.16M | 3 month · $3.56M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | (m) | $1.41B | (m) | $82.05M | (m) | $-48.13M | (m) | $-1.35B | (m) | $97.37M | 12 month · $8.99M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | (m) | $1.41B | (m) | $81.42M | (m) | $-48.09M | (m) | $-1.33B | (m) | $106.89M | 3 month · $2.16M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | (m) | $1.40B | (m) | $81.75M | (m) | $-48.31M | (m) | $-1.31B | (m) | $122.45M | 3 month · $3.18M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | (m) | $1.38B | (m) | $80.22M | (m) | $-48.37M | (m) | $-1.29B | (m) | $114.64M | 3 month · $2.01M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | (m) | $1.35B | (m) | $81.27M | (m) | $-48.42M | (m) | $-1.28B | (m) | $106.02M | 12 month · $9.30M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | (m) | $1.35B | (m) | $79.55M | (m) | $-48.88M | (m) | $-1.26B | (m) | $119.34M | 3 month · $2.48M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | (m) | $1.34B | (m) | $77.20M | (m) | $-49.47M | (m) | $-1.24B | (m) | $134.69M | 3 month · $2.96M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | (m) | $1.34B | (m) | $74.24M | (m) | $-49.63M | (m) | $-1.22B | (m) | $143.91M | 3 month · $2.13M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | $1.32B | (m) | $72.41M | (m) | $-50.49M | (m) | $-1.20B | (m) | $136.85M | 12 month · $7.18M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | (m) | $1.31B | (m) | $70.74M | (m) | $-51.00M | (m) | $-1.18B | (m) | $145.52M | 3 month · $1.72M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | (m) | $1.30B | (m) | $69.13M | (m) | $-50.10M | (m) | $-1.16B | (m) | $153.14M | 3 month · $2.06M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | (m) | $1.30B | (m) | $67.15M | (m) | $-49.41M | (m) | $-1.15B | (m) | $165.84M | 3 month · $1.74M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | $1.29B | (m) | $65.48M | (m) | $-48.34M | (m) | $-1.13B | (m) | $169.44M | 12 month · $6.38M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | (m) | $1.07B | (m) | $64.10M | (m) | $-48.19M | (m) | $-1.11B | (m) | $130.14M | 3 month · $1.55M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | $1.02B | (m) | $63.93M | (m) | $-48.20M | (m) | $-1.09B | (m) | $100.83M | 3 month · $1.76M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | $1.01B | (m) | $62.13M | (m) | $-48.17M | (m) | $-1.07B | (m) | $114.15M | 3 month · $1.65M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | $985.94M | (m) | $60.75M | (m) | $-48.17M | (m) | $-1.05B | (m) | $101.97M | 12 month · $6.14M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | (m) | $965.37M | (m) | $59.61M | (m) | $-48.13M | (m) | $-1.03B | (m) | $97.34M | 3 month · $1.66M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | $916.07M | (m) | $58.30M | (m) | $-48.10M | (m) | $-1.00B | (m) | $65.51M | 3 month · $1.60M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | $911.10M | (m) | $56.80M | (m) | $-47.98M | (m) | $-986.93M | (m) | $73.26M | 3 month · $1.46M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | $898.53M | (m) | $55.25M | (m) | $-48.23M | (m) | $-970.09M | (m) | $72.74M | 12 month · $7.20M | (m) | (m) | (m) | 12 month · $1.13M | (m) | (m) | (m) |
| 2019-09-30 | (m) | $884.62M | (m) | $55.38M | (m) | $-48.22M | (m) | $-942.56M | (m) | $83.64M | 3 month · $1.59M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | $884.62M | (m) | $53.74M | (m) | $-48.24M | (m) | $-857.26M | (m) | $164.47M | 3 month · $3.92M | (m) | (m) | (m) | 3 month · $135.00K | (m) | (m) | (m) |
| 2019-03-31 | (m) | $882.14M | (m) | $49.59M | (m) | $-48.19M | (m) | $-831.19M | (m) | $181.21M | 3 month · $1.67M | (m) | (m) | (m) | 3 month · $135.00K | (m) | (m) | (m) |
| 2018-12-31 | (m) | $879.40M | (m) | $48.08M | (m) | $-48.17M | (m) | $-805.22M | (m) | $200.23M | 12 month · $6.69M | (m) | (m) | (m) | 12 month · $1.13M | (m) | (m) | (m) |
| 2018-09-30 | (m) | $878.80M | (m) | $45.50M | (m) | $-48.20M | (m) | $-784.33M | (m) | $215.27M | 3 month · $1.66M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | $878.19M | (m) | $44.43M | (m) | $-48.19M | (m) | $-757.28M | (m) | $238.07M | 3 month · $1.86M 6 month · $3.37M | $66.27M | (m) | (m) | 6 month · $135.00K | (m) | (m) | (m) |
| 2018-03-31 | (m) | $876.29M | (m) | $43.77M | (m) | $-48.19M | (m) | $-757.84M | (m) | $232.42M | 3 month · $1.51M | $66.27M | (m) | (m) | 3 month · $135.00K | (m) | (m) | (m) |
| 2017-12-31 | (m) | $876.11M | (m) | $42.84M | (m) | $-48.19M | (m) | $-738.07M | (m) | $182.47M | 12 month · $14.86M | $48.87M | (m) | (m) | 12 month · $1.13M | (m) | (m) | (m) |
| 2017-09-30 | (m) | $876.05M | (m) | $40.76M | (m) | $-49.78M | (m) | $-699.63M | (m) | $167.39M | 9 month · $13.17M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | (m) | $873.84M | (m) | $39.76M | (m) | $-49.78M | (m) | $-688.03M | (m) | $175.79M | 6 month · $9.49M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | (m) | $870.85M | (m) | $37.81M | (m) | $-49.78M | (m) | $-669.78M | (m) | $189.10M | 3 month · $4.43M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | (m) | $867.39M | (m) | $36.54M | (m) | $-48.19M | (m) | $-652.75M | (m) | $203.00M | 12 month · $38.16M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-09-30 | (m) | $864.38M | (m) | $34.49M | (m) | $-49.78M | (m) | $-432.45M | (m) | $416.62M | 9 month · $33.54M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-06-30 | (m) | $861.15M | (m) | $32.82M | (m) | $-49.78M | (m) | $-412.86M | (m) | $431.32M | 6 month · $29.28M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-03-31 | (m) | $840.48M | (m) | $30.24M | (m) | $-49.78M | (m) | $-282.86M | (m) | $538.08M | 3 month · $7.91M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-12-31 | (m) | $834.24M | (m) | $30.21M | (m) | $-49.78M | (m) | $-266.99M | (m) | $547.68M | 12 month · $22.09M | (m) | (m) | (m) | 12 month · $4.08M | (m) | (m) | (m) |
| 2015-09-30 | (m) | $828.58M | (m) | $28.54M | (m) | $-41.59M | (m) | $-261.72M | (m) | $553.81M | 9 month · $14.73M | (m) | (m) | (m) | 9 month · $9.70M | (m) | (m) | (m) |
| 2015-06-30 | (m) | $821.66M | (m) | $27.84M | (m) | $-28.26M | (m) | $-232.74M | (m) | $588.50M | 6 month · $7.23M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-03-31 | (m) | $814.44M | (m) | $28.59M | (m) | $-31.49M | (m) | $-217.85M | (m) | $593.69M | 3 month · $2.93M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-12-31 | (m) | $290.00M | (m) | $26.21M | (m) | $-22.31M | (m) | $-205.86M | (m) | $88.03M | 12 month · $3.28M | (m) | (m) | (m) | 12 month · $2.46M | (m) | (m) | (m) |
| 2014-09-30 | (m) | $288.36M | (m) | $25.87M | (m) | $-19.04M | (m) | $-199.70M | (m) | $95.50M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 9 month · $2.71M |
| 2014-06-30 | (m) | $284.79M | (m) | $25.66M | (m) | $-14.21M | (m) | $-191.09M | (m) | $105.14M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 6 month · $2.27M |
| 2014-03-31 | (m) | $283.64M | (m) | $24.84M | (m) | $-17.98M | (m) | $-185.01M | (m) | $105.48M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 3 month · $1.19M |
| 2013-12-31 | 216.70M | $216.70M | 25.34M | $25.34M | -15.83M | $-15.82M | -167.03M | $-167.03M | 59.19M | $59.19M | 12 month · $903.00K | (m) | $15.83M | (m) | 12 month · $2.46M | (m) | (m) | 12 month · $903.00K |
| 2012-12-31 | 181.79M | (m) | 24.79M | (m) | -12.69M | (m) | -152.96M | (m) | 40.92M | $40.92M | 12 month · $982.00K | (m) | $12.69M | 12 month · 178.41K | (m) | 12 month · 8.50M | 12 month · 981.66K | 12 month · $982.29K |
| 2011-12-31 | 233.50M | (m) | 30.66M | (m) | (m) | (m) | -258.85M | (m) | 5.32M | $5.23M | (m) | (m) | $13.16M | 12 month · 475.57K | (m) | 12 month · 742.81K | 12 month · 626.12K | 12 month · $633.45K |
| 2010-12-31 | 229.49M | (m) | 30.15M | (m) | (m) | (m) | -248.91M | (m) | 10.73M | $10.79M | (m) | (m) | (m) | (m) | (m) | (m) | 12 month · 650.62K | (m) |
| 2009-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 22.46M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 12 month · 265.69K | (m) |
| 2008-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 30.94M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |